AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Sep 22, 2023
OCALA, Fla., Sept. 22, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at...
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
Sep 11, 2023
Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to pembrolizumab/neoadjuvant chemotherapy (NAC) Planned Phase 2 study in...
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Sep 5, 2023
OCALA, Fla., Sept. 05, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September...
AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements
Aug 23, 2023
Group Seeking to Take Control of 75% of AIM Board Failed to Properly Disclose Myriad Interconnections, Understandings and Arrangements Among Its Members - Violating the Company's Bylaws and Preventing Shareholders from Being Able to Make Fully Informed Decisions...
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
Aug 15, 2023
- Continued operational execution across pipeline towards multiple clinical and regulatory value-driving milestones expected in the second half of 2023 - Company to host conference call and webcast today at 8:30 AM ET OCALA, Fla., Aug. 15, 2023 -- AIM ImmunoTech Inc....
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
Aug 9, 2023
OCALA, Fla., Aug. 09, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") announced today that management will host a conference call and webcast to discuss the Company's Q2 2023 operational and financial results on Tuesday, August 15, 2023 at...
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Aug 8, 2023
Topline data expected as early as Q1 2024OCALA, Fla., Aug. 08, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM") today announced the completion of enrollment in the company's Phase 2 study evaluating Ampligen® as a potential therapeutic for people with...
AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates
Jul 18, 2023
OCALA, Fla., July 18, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today issued a notice that the Company has learned that unknown person(s) and/or organization(s) are claiming to represent AIM ImmunoTech Europe and are using the Company's...
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Jul 10, 2023
Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM") today announced it has enrolled...
AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series
Jul 5, 2023
Live moderated video webcast on Wednesday, July 12th at 11:00 AM ETOCALA, Fla., July 05, 2023 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types...